01.12.2017 | Research article | Ausgabe 1/2017 Open Access

Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Background
Methods
Statistical analysis
Results
Patient characteristics
No. of patients (%)
|
|
---|---|
Age
|
median, 47
|
Clinical FIGO stage
|
|
IA2
|
1 (1.0)
|
IB1
|
71 (72.5)
|
IB2
|
24 (24.5)
|
IIA
|
2 (2.0)
|
Histology
|
|
Squamous cell carcinoma
|
74 (75.5)
|
non-squamous cell carcinoma
|
24 (24.5)
|
SCC Ag
|
|
≤ 2 ng/ml
|
50 (51.0)
|
> 2 ng/ml
|
46 (47.0)
|
unknown
|
2 (2.0)
|
Tumor size
|
|
≤ 4 cm
|
50 (51.0)
|
> 4 cm
|
42 (42.9)
|
unknown
|
6 (6.1)
|
Deep stromal invasion
|
|
absent
|
23 (23.5)
|
present
|
75 (76.5)
|
Lymphovascular space invasion
|
|
absent
|
4 (4.1)
|
present
|
92 (93.9)
|
unknown
|
2 (2.0)
|
Parametrial invasion
|
|
negative
|
84 (85.7)
|
positive
|
14 (14.3)
|
Resection margin
|
|
negative
|
56 (57.1)
|
close (<5 mm)
|
9 (9.2)
|
positive
|
33 (33.7)
|
Pelvic lymph node metastasis
|
|
negative
|
19 (19.4)
|
positive
|
79 (80.6)
|
LNR
|
|
< 0.25
|
87 (88.8)
|
≥ 0.25
|
11 (10.2)
|
No. of high risk factor
|
|
1
|
66 (67.3)
|
2
|
27 (27.6)
|
3
|
5 (5.1)
|
Treatment compliance
Survival rate
RFS
|
CSS
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
variables
|
5 yr. rate
|
p value
|
HR
|
95% CI
|
p value
|
5 yr. rate
|
p value
|
HR
|
95% CI
|
p value
|
size >4 cm
|
0.304
|
0.073
|
2.781
|
0.710–10.990
|
0.142
|
|||||
no
|
92.0
|
93.9
|
||||||||
yes
|
83.1
|
87.9
|
||||||||
SCC Ag
|
0.611
|
0.904
|
||||||||
≤ 2 ng/mL
|
88.0
|
89.9
|
||||||||
> 2 ng/mL
|
86.9
|
91.2
|
||||||||
DSI
|
0.985
|
0.778
|
||||||||
absent
|
86.4
|
90.7
|
||||||||
present
|
87.9
|
90.6
|
||||||||
LVSI
|
0.671
|
0.720
|
||||||||
absent
|
100.0
|
100.0
|
||||||||
present
|
86.9
|
90.1
|
||||||||
PM invasion
|
0.145
|
0.196
|
||||||||
absent
|
85.7
|
89.2
|
||||||||
present
|
100.0
|
100.0
|
||||||||
RM
|
0.052
|
2.868
|
0.881–9.333
|
0.080
|
0.132
|
|||||
clear
|
92.8
|
92.7
|
||||||||
close or positive
|
81.0
|
88.0
|
||||||||
LN metastasis
|
0.664
|
0.932
|
||||||||
absent
|
88.8
|
88.2
|
||||||||
present
|
87.3
|
91.1
|
||||||||
No. of positive LN
|
0.021
|
3.179
|
1.066–9.477
|
0.038
|
0.005
|
4.004
|
1.130–14.195
|
0.032
|
||
0–2
|
92.8
|
94.5
|
||||||||
≥ 3
|
74.1
|
81.5
|
||||||||
LNR
|
0.018
|
2.330
|
0.611–8.879
|
0.215
|
0.011
|
1.740
|
0.391–7.740
|
0.467
|
||
< 0.25
|
90.7
|
91.8
|
||||||||
≥ 0.25
|
63.6
|
81.8
|
||||||||
No. of risk factors
|
0.299
|
0.345
|
||||||||
1
|
90.8
|
90.7
|
||||||||
2–3
|
81.3
|
90.6
|
Toxicities
variables
|
Percent
|
---|---|
Hematologic
|
|
leukopenia
|
36.5
|
neutropenia
|
11.5
|
anemia
|
8.7
|
thrombocytopenia
|
1.0
|
Gastrointestinal
|
|
anorexia
|
1.9
|
nausea/vomiting
|
1.9
|
diarrhea
|
6.7
|
proctitis
|
1.0
|
small bowel obstruction
|
4.8
|
Lymphedema
|
1.0
|